Johnson & Johnson (NYSE:JNJ) Shares Purchased by Forza Wealth Management LLC

Forza Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 3.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,463 shares of the company’s stock after acquiring an additional 342 shares during the period. Forza Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,369,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Accelerate Investment Advisors LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at about $258,000. Cooper Financial Group lifted its holdings in Johnson & Johnson by 4.2% in the 4th quarter. Cooper Financial Group now owns 10,449 shares of the company’s stock valued at $1,511,000 after purchasing an additional 422 shares in the last quarter. Talbot Financial LLC lifted its holdings in shares of Johnson & Johnson by 2.8% during the 4th quarter. Talbot Financial LLC now owns 101,236 shares of the company’s stock worth $14,641,000 after acquiring an additional 2,733 shares during the period. Salem Investment Counselors Inc. lifted its holdings in shares of Johnson & Johnson by 0.3% during the 4th quarter. Salem Investment Counselors Inc. now owns 179,539 shares of the company’s stock worth $25,965,000 after acquiring an additional 503 shares during the period. Finally, QV Investors Inc. lifted its holdings in shares of Johnson & Johnson by 7.8% during the 4th quarter. QV Investors Inc. now owns 104,940 shares of the company’s stock worth $15,176,000 after acquiring an additional 7,570 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.7 %

Shares of JNJ stock traded up $2.43 during mid-day trading on Monday, reaching $144.49. 5,615,731 shares of the company were exchanged, compared to its average volume of 7,666,393. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market capitalization of $347.88 billion, a P/E ratio of 20.91, a P/E/G ratio of 2.52 and a beta of 0.51. The business’s 50 day simple moving average is $149.67 and its 200 day simple moving average is $156.11.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the company earned $2.66 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Guggenheim increased their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Bank of America reiterated a “neutral” rating and set a $166.00 price objective on shares of Johnson & Johnson in a report on Tuesday, December 10th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 7th. Finally, Morgan Stanley raised their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $174.71.

Read Our Latest Stock Analysis on JNJ

Insiders Place Their Bets

In related news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.